pharmaphorum22m
Roche ends the 30-year US hiatus in new stroke drugs
In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...
Hosted on MSN58m
FDA approves Genentech’s TNKase® in acute ischemic stroke in adults
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...